## AMENDMENTS

**Listing of Claims:**

**The following listing of claims replaces all previous listings or versions thereof:**

1.-4. (Canceled)

5. (Currently amended) The method of ~~claim 1~~ claim 12, wherein said retinoid is a material selected from the group consisting of all-*trans*-retinoic acid (RA); 9-*cis* retinoic acid (9-cis RA); (*E*)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-nephthalenyl)-1-propenyl]benzoic acid (TTNPB); and, (*E*)-4-[2-(5,6,7,8,-tetrahydro-3,5,5,8,8-pentamethyl–2-nephthalenyl)-1-propenyl]benzoic acid (3-met TTNPB).

6. (Currently amended) The method of ~~claim 5~~ claim 12, wherein said retinoid is administered in a dose of from about 0.1 mg/kg to about 2 mg/kg.

7. (Canceled)

8. (Currently amended) The method of ~~claim 7~~ claim 12, wherein said immunotoxin comprises a monoclonal antibody directed against the CD38 antigen conjugated to a toxin molecule.

9. (Original) The method of claim 8, wherein said toxin is gelonin.

10. (Canceled)

11. (Currently amended) The method of ~~claim 1~~ claim 12, wherein said immunotoxin is administered in a dose of from about 0.05 mg/kg to about 2 mg/kg.

12. (Currently amended) A method of treating an individual having a ~~The method of claim 1, wherein said pathophysiological state comprises~~ drug-resistant leukemia, comprising the steps of:

a) administering to said individual a pharmacologically effective dose of a retinoid which up-regulates the expression of CD38 antigen; and,

b) administering to the same individual a pharmacologically effective dose of an immunotoxin directed against CD38 antigen.

13. (Previously presented) The method of claim 12, wherein said drug-resistant leukemia is adriamycin-resistant leukemia.

14. – 15. (Canceled)